The approval was based on data from the FIBRONEER-IPF trial, where the drug showed: A smaller decline in Forced Vital Capacity (FVC) over 52 weeks versus placebo Benefits visible as early as week 2 A favourable safety profile A huge milestone for patients living with IPF
Grauslund J, Taha AA, Molander LD, Kawasaki R, Mller S, Hjlund K, et al
Langers No Worries GLP-1 Support Beverage does not replicate prescription treatments, but it enters the broader conversation by focusing on fiber intake and gut health, two areas often discussed alongside metabolic wellness
Difference between the groups will be analyzed adjusted for baseline RBANS
This process not only supports energy levels but also aids in the metabolism of carbohydrates, making it a valuable supplement for those looking to enhance their physical performance and overall vitality